United States / USD Country & Currency
Country
United States
Currency
US Dollars
Save
Country
Australia
Gibraltar
Hong Kong
Malta
Northern Ireland
Puerto Rico
Scotland
Singapore
Switzerland
United Kingdom
United States
Currency
US Dollars
GB Pounds
AU Dollars
Euro
Explore our range Categories
Ask us a question 877-271-6591 or 800-868-9064
ATTENTION: US CUSTOMERS

Please be advised that there are currently significant Customs Processing Delays at JFK, NY and Newark, NJ ports of entry.

Please understand that these delays are outside our control—We sincerely apologise for any inconvenience encountered. Please consider ordering in advance to allow for longer than usual delays.

Shipping delays due to Covid-19 Virus

Please fill the form to receive updates when we can ship your order.

Anti-Androgens

Our Anti-Androgens class of Womans/HRT medications are used to treat androgenisation in women caused by overproduction of androgens that results in symptoms including hirsutism, androgenic alopecia and acne. 

Use the search feature to quickly find the product you are looking for by entering either the active ingredient, e.g. Cyproterone or the product name e.g. Siterone.  

Androgenisation in women

Although androgens such as testosterone are considered to be male hormones, women also produce some androgen but in much smaller amounts.  However, some women produce too much testosterone and this condition is known as androgenisation.  The symptoms of androgenisation include hirsutism, which is unwanted hair in the male pattern, and includes the face, chest and back and is usually thickened and pigmented.  This condition is also associated with acne and/or seborrhoea (greasy skin from too much sebum) and androgen-dependent alopecia (hair loss).  

Anti-Androgens

Treatment of overproduction of androgens is based on blocking the androgen receptor, which prevents testosterone binding to its receptor to reduce the effectiveness of the hormone.  
Read more
 

This website uses cookies. View our policy and select your preferences here